Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10624	SCR7
BP10624	SCR7, a specific DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ).
BP10588	SCR7 pyrazine
BP10588	Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).
BP10768	Scutebarbatine A
BP10768	Scutebarbatine A shows significant antitumor effects on A549 cells in vivo and in vitro via mitochondria-mediated apoptosis by up-regulating expressions of caspase-3 and 9, and down-regulating Bcl-2. Scutebarbatine A and barbatine A show a significant ability to protect cells against H2O2 with ED50 values of 5.0 and 16.8 μM, respectively.
BP10887	Selinidin
BP10887	Selinidin decreases phosphorylation of phospholipase C-gamma1, p38 mitogen-activated protein kinase, and IkappaB-alpha upon FcepsilonRI stimulation.
BP10549	Selonsertib
BP10549	Selonsertib is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.
BP10937	Semaxinib
BP10937	Semaxanib (SU5416) is a potent and selective VEGFR2 inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR than PDGFRβ, lack of activity against InsR, EGFR, and FGFR. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature.
BP10339	Sennoside B
BP10339	Sennoside B is an anthranoid. Anthranoid derivatives are used all over the world as a treatment for constipation.
BP10683	Seralutinib
BP10683	Seralutinib is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.
BP10245	Setanaxib
BP10245	GKT137831 is a potent, specific dual NADPH oxidase (NOX1/4) inhibitor.
BP10029	SGI-1027
BP10029	SGI-1027 is an effective and selective inhibitor of DNA methyltransferase (DNMT). The IC50 of SGI-1027 against DNMT1, DNMT3A, and DNMT3B are 6, 8, 7.5 μM, respectively.
BP10039	SGI-1776
BP10039	SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.
BP10286	SGI-7079
BP10286	SGI-7079 is a new selective Axl inhibitor. SGI-7079 can be a dose-dependent manner inhibited growth of tumors. It is also a potential therapeutic target for EGFR inhibitor resistance.
BP10035	SGX-523
BP10035	SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
BP10504	Shizukaol B
BP10504	Shizukaol B exerts anti-inflammatory effects in LPS-activated microglia partly by modulating JNK-AP-1 signaling pathway; it also shows significant anti-neuroinflammatory effects by inhibiting nitric-oxide (NO) production in lipopolysaccharide (LPS)-stimulated murine BV-2 microglial cells with relatively low cytotoxicity. Shizukaol B exhibits anti-HIV-1 replication activities in both wild-type HIV-1 and two NNRTIs-resistant strains, it also has significant cytotoxicities against C8166 cells. Shizukaol B prevents monocyte adhesion to HUVEC through the inhibition of cell adhesion molecules expression stimulated by TNF-alpha.
BP10797	SHP099
BP10797	SHP099 free base is an effective, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM). SHP099 shows dose-dependent pathway inhibition and antitumor activity in xenograft models.
BP10542	SHR0302
BP10542	SHR0302 is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 420 times for Tyk2).
BP10706	Sigma-1 receptor antagonist 3
BP10706	Sigma-1 receptor antagonist 3 is a more potent and selective antagonist of Sigma-1 (σ1) receptor (Ki = 1.14 nM) than σ2 receptor(Ki = 1239 nM). Sigma-1 receptor antagonist 3 inhibits Human Ether-a-go-go-Related Gene (hERG, IC50 = 1.54 μM)
BP10465	Sildenafil
BP10465	Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor, used to treat erectile dysfunction and reduce symptoms of pulmonary arterial hypertension (PAH).
BP10755	Sildenafil citrate
BP10755	Sildenafil, a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) Inhibitor, is used extensively for erectile dysfunction and less commonly for pulmonary hypertension.
BP10178	Sinomenine
BP10178	Sinomenine is a pure alkaloid isolated from the Sinomenium acutum, is utilized in the treatment of rheumatism and arthritis.